{
      "Rank": 34,
      "Acronym": [
            "EMMES"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.",
            "Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6."
      ],
      "ArmGroupInterventionName": [
            "Drug: XCEL-MC-ALPHA",
            "Drug: Placebo",
            "Drug: XCEL-MC-ALPHA",
            "Drug: Placebo"
      ],
      "ArmGroupLabel": [
            "Treatment A: XCEL-MC-ALPHA/Placebo",
            "Treatment B: Placebo/XCEL-MC-ALPHA"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02495766"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This study evaluates the effect of cryopreserved autologous adult bone-marrow mesenchymal stromal cells (BM-MSC) in patients with active multiple sclerosis, compared to placebo.\n\nPatients will be allocated to one of the 2 treatment arms (BM-MSC or placebo)and at month 6, the treatment will be crossed to receive the other product. The objective is to assess the safety of a single infusion BM-MSC, and to explore its efficacy in these patients.\n\nPatients will be evaluated at month 12 and will be followed-up for a total of 3 years."
      ],
      "BriefTitle": [
            "Autologous Mesenchymal Stromal Cells for Multiple Sclerosis"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "UNKNOWN"
      ],
      "CollaboratorName": [
            "Vall d'Hebron Research Institute (VHIR)"
      ],
      "CompletionDate": [
            "November 15, 2018"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Relapsing-Remitting Multiple Sclerosis",
            "Secondary Progressive Multiple Sclerosis"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000020278",
            "D000020274",
            "D000009422",
            "D000003711",
            "D000001327",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Demyelinating Autoimmune Diseases, CNS",
            "Autoimmune Diseases of the Nervous System",
            "Nervous System Diseases",
            "Demyelinating Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "BC20",
            "All",
            "BC23",
            "BC04",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "Immune System Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Neoplasms",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Multiple Sclerosis",
            "Sclerosis",
            "Secondary Progressive Multiple Sclerosis",
            "Relapsing Remitting Multiple Sclerosis"
      ],
      "ConditionBrowseLeafId": [
            "M11212",
            "M14567",
            "M3781",
            "M11459",
            "M21466",
            "M21467",
            "M6061",
            "M21251",
            "M21247",
            "M9352",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Multiple Sclerosis",
            "Sclerosis",
            "Autoimmune Diseases",
            "Neoplasm Metastasis",
            "Multiple Sclerosis, Chronic Progressive",
            "Multiple Sclerosis, Relapsing-Remitting",
            "Demyelinating Diseases",
            "Demyelinating Autoimmune Diseases, CNS",
            "Autoimmune Diseases of the Nervous System",
            "Immune System Diseases",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000009103",
            "D000020529",
            "D000020528",
            "D000012598"
      ],
      "ConditionMeshTerm": [
            "Multiple Sclerosis",
            "Multiple Sclerosis, Relapsing-Remitting",
            "Multiple Sclerosis, Chronic Progressive",
            "Sclerosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Crossover Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "To date, there is no effective therapy to cure multiple sclerosis (MS). Immunomodulatory therapies are useful in reducing the frequency of inflammatory processes (relapses) but don't delay significantly the progression of the disease, prevent long term disability or induce the repair of damaged tissue. This proposal contemplates the use of adult autologous bone marrow mesenchymal stromal cells (BM-MSC) as an alternative therapeutic strategy to treat patients with active MS. This is a randomized, double blind, crossover clinical trial in which 8 patients with active forms of MS and moderate disability will enter the trial with the primary objective of assessing the safety and tolerability of a single intravenous infusion of BM-MSC. Secondary objectives are to assess the efficacy by gadolinium enhancing lesions though magnetic resonance imaging, neurophysiological effects and immunological effects. Once randomized, patients will undergo BM extraction and once confirmed the availability of the needed dose, they will be randomized to one of the 2 treatment arms (BM-MSC named XCEL-MC-ALPHA, or placebo). XCEL-MC-ALPHA will be cryopreserved for all patients regardless the allocated arm. At month 6, the treatment will be crossed. Patients will be evaluated at month 12 and will be followed-up for a total of 3 years."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients between 18 and 60 years of age\nPatients with MS\nRelapsing-remitting or secondary progressive MS\nPatients to whom are not indicated or are not in a position to initiate treatment with disease-modifying drugs\nExpanded Disability Status Scale (EDDS) score <6.5\nNine T2 lesions at least\nActive multiple sclerosis as defined either by 1 outbreak in the last year or at least one Gadolinium-enhancing lesion in the last 6 months\nSigned informed consent form\n\nExclusion Criteria:\n\nInterferon beta or glatiramer acetate 3 months prior the screening\nNatalizumab or fingolimod in the 6 months prior the screening\nMitoxantrone, cyclophosphamide or other immunosuppressive therapy at any time\nHas received an experimental treatment within 3 months prior the screening\nMS outbreak within the 4 weeks prior the randomization\nSerum creatinine> 2.0 mg/dl\nInfectious disease active or uncontrolled\nFertile patients who are not using a suitable method of contraception\nPregnant or lactating woman\nImmunodeficiency\nPositive serology to HIV, Hepatitis B, Hepatitis C or syphilis"
      ],
      "EnrollmentCount": [
            "8"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Treatment A: XCEL-MC-ALPHA/Placebo",
            "Treatment B: Placebo/XCEL-MC-ALPHA",
            "Treatment A: XCEL-MC-ALPHA/Placebo",
            "Treatment B: Placebo/XCEL-MC-ALPHA"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Single infusion",
            "Single infusion"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "XCEL-MC-ALPHA",
            "Placebo"
      ],
      "InterventionOtherName": [
            "Bone-marrow mesenchymal stromal cells"
      ],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Multiple sclerosis",
            "Bone marrow mesenchymal stromal cells",
            "Stem cells",
            "Nervous System Diseases",
            "Demyelinating Diseases",
            "Autoimmune Diseases"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 21, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 15, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Banc de Sang i Teixits"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Barcelona"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Spain"
      ],
      "LocationFacility": [
            "Hospital Vall Hebron"
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [
            "08005"
      ],
      "MaximumAge": [
            "60 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Banc de Sang i Teixits"
      ],
      "OrgStudyId": [
            "XCEL-MS-02"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hospital Vall d'Hebron"
      ],
      "OverallOfficialName": [
            "Xavier Montalban, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "November 27, 2017"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Safety profile"
      ],
      "PrimaryOutcomeMeasure": [
            "Adverse events"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Imaging procedure",
            "Medical assessment",
            "Quantification of disability",
            "Imaging procedure"
      ],
      "SecondaryOutcomeMeasure": [
            "Cumulative number of MRI Gd-enhancing lesions",
            "Multiple Sclerosis Outbreaks",
            "Expanded Disability Status Scale (EDDS) score",
            "Cumulative number of lesions visualized on T2 sequence"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 months",
            "12 months",
            "12 months",
            "12 months"
      ],
      "SeeAlsoLinkLabel": [
            "Blood and Tissue Bank of Catalonia",
            "Multiple Sclerosis center of Catalonia",
            "Vall d'Hebron Research Institute"
      ],
      "SeeAlsoLinkURL": [
            "http://www.bancsang.net",
            "http://www.cem-cat.org/",
            "http://www.vhir.org"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 11, 2015"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2020"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "July 13, 2015"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "June 3, 2015"
      ],
      "StudyFirstSubmitQCDate": [
            "July 8, 2015"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}